IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World’s Most Admired ...

IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on IQVIA Holdings (IQV – Research Report). The ...

Shares of Centene Corp. slid 5.45% to $61.29 Tuesday, on what proved to be an all-around positive trading session for the ...

Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life ...

Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 ...

Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which ...

While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia ...

(HealthDay News) — Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in October ...

Concussions were down 17 percent from 2023 and were the lowest on record since the league started tracking data in 2015.

IQVIA Holdings Inc. closed 22.27% below its 52-week high of $261.73, which the company achieved on March 8th.